The job cuts and consolidation efforts are expected to save the debt-ridden drugmaker $3 billion in annual costs, after an upfront charge of $700 million in severance expenses and facility closures.
Its U.S. consolidation efforts will include closing sites in Cambridge, Mass., Washington, D.C., Horsham, Pa., and New York City. In addition, some other sites may be sold to competitors, according to the report.
The company has yet to decide the location of its consolidated U.S. site.
The announcement comes after Teva lost a lawsuit Monday that attempted to block Mylan’s generic multiple sclerosis drug from entering the U.S. market.
More articles on supply chain:
10 recent pharma layoffs
Sanofi urges Philippine government to lift suspension of its dengue vaccine
Medline to relocate supply distribution center in Maryland, triple its workforce
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
